UnknownPhase 2

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

South Korea32 participantsStarted 2013-06

Plain-language summary

To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive diseases following hematopoietic stem cell transplantation.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with hepatic veno-occlusive disease after hematopoietic stem cell transplantation. The following criteria will be used.
✓. Two of the following
✓. Patients with pathologic diagnosis.
✓. Patients with informed consent

Exclusion criteria

✕. Pregnant or nursing women.
✕. Malignant or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.
✕. Psychiatric disorder that would preclude compliance.
✕. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
✕. History of anaphylactic reaction to the study drug

What they're measuring

AT-III level before 5th dose of AT-III

Timeframe: up to 14 days

Trial details

NCT IDNCT01886248

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08

View on ClinicalTrials.gov More Hepatic Veno-Occlusive Disease trials